

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN: 2167-8421 (Print) 2167-9223 (Online) Journal homepage: <https://www.tandfonline.com/loi/iafd20>

ALSUntangled 57: Vinpocetine

THE ALSUNTANGLED GROUP

To cite this article: THE ALSUNTANGLED GROUP (2020): ALSUntangled 57: Vinpocetine, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: [10.1080/21678421.2020.1786942](https://doi.org/10.1080/21678421.2020.1786942)

To link to this article: <https://doi.org/10.1080/21678421.2020.1786942>



Published online: 01 Jul 2020.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)



RESEARCH ARTICLE

ALSUntangled 57: Vinpocetine

THE ALSUNTANGLED GROUP

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS). Here we review Vinpocetine for which we have had over 600 requests (1).

Overview

Vinpocetine (chemical name 14-ethoxycarbonyl-(3a,16a-ethyl)-14,15-eburnamine) is a product derived from an alkaloid substance in the periwinkle plant *Vinca minor* (2). In many countries it is classified as a prescription drug and is used for the treatment of acute stroke and cognitive impairment (3), although systematic reviews have failed to confirm any benefits for patients with these conditions (4,5). In the United States, it is classified as a nutritional supplement (3). At least one website claims that Vinpocetine might be “beneficial for ALS” (6). A published case series demonstrated that Vinpocetine was associated with reduced cramping in PALS and suggested further study, including determining whether it could slow ALS progression (7). This review examines Vinpocetine’s potential role in slowing ALS progression.

Mechanistic plausibility

Orally and intravenously administered Vinpocetine enters the CSF and brain (8). There it may plausibly affect at least 5 ALS mechanisms: hyperexcitability, excitotoxicity, oxidative stress, neuroinflammation and mitochondrial dysfunction.

Hyperexcitability

Cortical hyperexcitability, as measured by transcranial magnetic stimulation, is common across

genetic and sporadic ALS subtypes (9), precedes the onset of lower motor neuron dysfunction and weakness (10), and correlates anatomically with the pattern of disease spread (11). Causes of cortical hyperexcitability include increased motor neuron sodium currents (12); riluzole may exert some of its survival benefit by reducing these currents (13). Vinpocetine can block neuronal voltage gated sodium channels (2,14), potentially reducing sodium currents and cortical hyperexcitability.

Excitotoxicity

We previously reviewed glutamate-induced neurotoxicity mediated via AMPA receptors as an ALS mechanism (15). Vinpocetine can block AMPA receptors and protect cultured cortical neurons against excitotoxicity (16,17). Riluzole may exert some of its survival benefit via decreasing excitotoxicity (18). Unfortunately, three other drugs that act on this pathway failed to help PALS in trials (19–21).

Oxidative stress

As discussed in a recent ALSUntangled paper, oxidative stress may contribute to ALS progression (22). While clinical trials of most antioxidants have shown no benefits (23,24), one trial found that Edaravone slightly slows disease progression in a subset of PALS (25). Vinpocetine can protect neuronal cultures from oxidative stress (26,27), and can decrease serum and tissue biomarkers of oxidative stress in a rat model of ischemia-reperfusion injury (28).

ALSUntangled Reviewers who contributed to this paper include the following: Richard Bedlack, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Bereman, Tulio Bertorini, Greg Carter, Amy Chen, Jesse Crayle, Merit Cudkowicz, Carlayne Jackson, Matthew Kiernan, Gleb Levitsky, Christopher McDermott, Gary Pattee, Erik Pioro, Kristiana Salmon, Kim Staats, James Stephens, Paul Wicks, others who contribute.

Note: this paper represents a consensus of those weighing in. The opinions expressed in this paper are not necessarily shared by every investigator in this group.

Correspondence: Richard Bedlack. Email: richard.bedlack@duke.edu

ISSN 2167-8421 print/ISSN 2167-9223 online © 2020 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases
DOI: 10.1080/21678421.2020.1786942

Table 1. Table of Evidence for vitamin Vinpocetine.

	Grade	Explanation
Mechanism	A	Vinpocetine can enter the brain and affect 5 mechanisms that are believed to be important in ALS: hyperexcitability, excitotoxicity, oxidative stress, neuroinflammation and mitochondrial dysfunction. Its effects on neuroinflammation biomarkers have been demonstrated in a human trial.
Pre-Clinical	U	We found no studies of Vinpocetine in recognized pre-clinical models of ALS.
Cases	D	We found 2 PALS reporting that supplement cocktails including Vinpocetine were associated with improved motor function, but we did not have records to independently verify their diagnoses or improvements.
Trials	U	We found no trials of Vinpocetine in PALS.
Risks	D	More than 0 but less than 5% of exposed patients experienced serious adverse events.

Neuroinflammation

Neuroinflammation, including activation of the NF- κ B cellular signaling pathway, may contribute to the pathophysiology of ALS (29–34). Down-regulating this pathway is beneficial in mouse models of ALS (31–34). Trials of immune-modulating therapies have thus far been unsuccessful in PALS (35), with the possible recent exception of Masitinib (36). Vinpocetine can inhibit I κ B kinase, ultimately downregulating NF- κ B mediated neuroinflammation (2,37,38). In a trial of patients with Parkinson’s disease, Vinpocetine treatment was associated with reductions in several inflammatory biomarkers including NF- κ B, toll-like receptors and cytokines (39).

Mitochondrial dysfunction

Many lines of evidence implicate mitochondrial dysfunction in the pathophysiology of ALS (40). Vinpocetine may have potentially beneficial effects on mitochondrial membrane currents and energy production, at least in cell cultures and isolated mitochondria (41,42).

Based on Vinpocetine’s ability to affect mechanisms believed to be important in ALS, including its ability to reduce biomarkers of neuroinflammation in a human trial, ALSUntangled assigns a “Mechanism” grade of “A” (Table 1).

Pre-clinical models

We found no studies of Vinpocetine in recognized pre-clinical models of ALS. Therefore ALSUntangled assigns a “Pre-Clinical” grade of “U” (Table 1).

Cases

In the online community PatientsLikeMe, nine people reported taking Vinpocetine for ALS; one completed detailed evaluations. At doses ranging from 5mg to 1000mg daily (43), they were unable to tell if it was helpful in any way. In the online forum ALS net, one person reported that a combination of supplements including Vinpocetine 400mg to 1000mg daily helped with “clarity of speech” (44). Another person reported that a supplement cocktail including Vinpocetine at 200mg to 1000mg daily was associated with improved dyspnea and increased arm and leg strength in their spouse who had ALS (44). We did not have medical records to independently verify the diagnoses or the reported improvements in these patients. One ALSUntangled reviewer (GL) cared for 11 PALS on Vinpocetine; they saw no obvious benefits. Based on this information, ALSUntangled assigns a “Cases” grade of “D” (Table 1).

Trials

We found no trials of Vinpocetine in PALS. Therefore we assign a “Trials” grade of “U” (Table 1).

Dosing, risks, costs

The optimal dose for PALS has not been established. In a case series of 27 PALS treated with Vinpocetine for cramps, the dose was 5mg three times daily for up to 24 months (7); no adverse events were noted. PALS online reported using 5mg to 1000mg per day (43,44). At these doses, some experienced side effects including dizziness, increased fasciculations, changes in body temperature and limb swelling (43,44). Human studies in patients with Parkinson’s disease (39), stroke (45,46), cognitive impairment (47–49) and various other non-neurological conditions (8) used oral or IV doses ranging from 1mg daily to 250mg twice daily, usually for short durations (<6 months). Adverse events in these trials were generally rare (<10% of participants) and non-serious, and included gastrointestinal discomfort, nausea, vertigo, headache, flushing, rash, anxiety, drowsiness and dry mouth. Some but not all studies reported a transient drop in blood pressure with treatment (8). We found three possible serious adverse events association with Vinpocetine. A patient receiving 15mg daily for stroke developed agranulocytosis (a serious and potentially life-threatening abnormality in white blood cell count); no other cause for this was found and it resolved with G-CSF (which stimulates blood cell production) and discontinuation of Vinpocetine (50). Two patients receiving 5mg three times daily for mild cognitive impairment experienced “acute respiratory disease” (51).

Based on this side effect profile, ALSUntangled assigns a “Risks” grade of “D” (Table 1).

At a dose of 10mg twice daily, the cost of Vinpocetine is \$8 per month (52). Unfortunately, as with many supplements, the labeled amount of Vinpocetine in different brands is often inaccurate when independently tested (53).

Conclusions

Vinpocetine has several plausible mechanisms by which it could slow ALS progression. There are two PALS online who reported improved motor functions on supplement cocktails containing Vinpocetine, but many other PALS have had no benefits. Serious side effects from Vinpocetine are rare and it is inexpensive. We support further study of Vinpocetine in ALS, but our group was split on what the next step should be; some were in favor of a study in a pre-clinical ALS model and others were in favor of a small human trial to confirm its benefit on cramps (7) and to explore whether it is safe, tolerable and might slow disease progression.

Disclosures of interest

ALSUntangled is sponsored by the ALS Association. Richard Bedlack has research support from ALSA and Orion, and consulting support from Alexion, ALSA, Amylyx, Biogen, Brainstorm Cell, ITF Pharma, Mallinkrodt, New Biotic and Woolsey Pharma.

References

1. ALSUntangled [online]. Available at: <http://www.alsuntangled.com/open.php>. Accessed June 5, 2020.
2. Zhang Y, Li J, Yan C. An update on vinpocetine: new discoveries and clinical implications. *Eur J Pharmacol*. 2018;819:30–830.
3. Cohen P. Vinpocetine: an unapproved drug sold as a dietary supplement. *Mayo Clin Proc*. 2015;90:1455–7.
4. Szatmari S, Whitehouse P. Vinpocetine for cognitive impairment and dementia. *Cochrane Database of Syst Rev*. 2003;1:CD003119.
5. Bereczki D, Fekete I. Vinpocetine for acute ischemic stroke. *Cochrane Database Syst Rev*. 2008;1:CD000480.
6. ALS Worldwide [online]. Available at: <https://alsworldwide.org/care-and-support/article/supplements-and-vitamins>. Accessed June 5, 2020.
7. de Carvalho M. Cramps and vinpocetine in ALS. *Amyotroph Lat Scl Frontotemporal Degener*. 2018;19:155–6.
8. NIEHS [online]. Available at: https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/vinpoce-tine091613_508.pdf. Accessed June 5, 2020.
9. Vucic S, Ziemann U, Eisen A, Hallet M, Kiernan M. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. *J Neurol Neurosurg Psychiatry*. 2013;84:1161–70.
10. Menon P, Kiernan M, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. *Clin Neurophys*. 2015;126:803–9.
11. Menon P, Geevasinga N, van den Bos M, Yiannikas C, Kiernan M, Vucic S. Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis. *Eur J Neurol*. 2017;24:816–24.
12. Pieri M, Carunchio I, Curcio L, Mercuri N, Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. *Exp Neurol*. 2009;215:368–79.
13. Vucic S, Lin C, Cheah B, Murray J, Menon P, Krishnan A, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. *Brain*. 2013;136:1361–70.
14. Sitges M, Galvan E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. *Neurochem Int*. 2005;46:533–40.
15. The ALSUntangled Group. ALSUntangled 48: Perampanel (Fycompa). *Amyotroph Lat Scl Fr*. 2019;20:453–6.
16. Erdö SL, Cai NS, Wolff JR, Kiss B. Vinpocetin protects against excitotoxic cell death in primary cultures of rat cerebral cortex. *Eur J Pharmacol*. 1990;187:551–3.
17. Kiss B, Cai NS, Erdö SL. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. *Eur J Pharmacol*. 1991;209:109–12.
18. Bellingham M. A Review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? *CNS Neurosci Ther*. 2011;17:4–31.
19. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. *Neurology* 2003;61:456–64.
20. Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomized, double-blind, placebo-controlled trial. *Lancet Neurol*. 2014;13:1083–91.
21. Teva [online]. Available at: <https://ir.tevapharm.com/investors/press-releases/press-release-details/2010/Teva-Provides-Update-on-Talampanel-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS/default.aspx>. Accessed December 16, 2018.
22. Bedlack R. ALSUntangled No. 47: RT001. *Amyotroph Lateral Scler Fr*. 2019;20:294–7.
23. Orrell R, Lane R, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. *Amyotroph Lateral Scler*. 2008;9:195–211.
24. Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II Trial of CoQ10 for ALS finds insufficient evidence to justify Phase III. *Ann Neurol*. 2009;66:235–44.
25. Writing Group on Behalf of the Edaravone ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2017;16:505–12.
26. Santos MS, Duarte AI, Moreira PI, Oliveira CR. Synaptosomal response to oxidative stress: effect of vinpocetine. *Free Radic Res*. 2000;32:57–66.
27. Herrera-Mundo N, Sitges M. Vinpocetine and atocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. *J Neurochem*. 2013;124:233–40.
28. Zaki H, Abdelsalam R. Vinpocetine protects liver against ischemia-reperfusion injury. *Can J Physiol Pharmacol*. 2013;91:1064–70.

29. Thonhoff J, Simpson E, Appel S. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. *Curr Opin Neurol.* 2018;3:635–9.
30. Sako W, Ito H, Yoshida M, Koizumi H, Kamada M, Fujita K, et al. Nuclear factor κ B expression in patients with sporadic amyotrophic lateral sclerosis and hereditary amyotrophic lateral sclerosis with optineurin mutations. *Clin Neuropathol.* 2012;31:418–23.
31. Swarup V, Phaneuf D, Dupré N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κ B-mediated pathogenic pathways. *J Exp Med.* 2011;208:2429–47.
32. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF- κ B pathway in amyotrophic lateral sclerosis. *Neuron* 2014;81:1009–23.
33. Patel P, Julien JP, Kriz J. Early-stage treatment with withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. *Neurotherapeutics.* 2015;12:217–33.
34. Lyon M, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity and amyotrophic lateral sclerosis: I. etiology and pathology. *Muscle Nerve.* 2019;59:10–22.
35. Wosiski-Kuhn M, Lyon M, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. *Muscle Nerve.* 2019;59:23–33.
36. Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Mastinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. *Amyotroph Lat Sci FR.* 2020;21:5–14.
37. Jeon K-I, Xu X, Aizawa T, Lim JH, Jono H, Kwon D-S, et al. Vinpocetine inhibits NF- κ B-dependent inflammation via an IKK-dependent but PDE-independent mechanism. *Proc Natl Acad Sci USA.* 2010;107:9795–800.
38. Medina A. Vinpocetine as a potent antiinflammatory agent. *Proc Natl Acad Sci USA.* 2010;107:9921–2.
39. Ping Z, Xiaomu W, Xufang X, Lian S. Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients. *Neurol Sci.* 2019;40:113–20.
40. Kodavati M, Wang H, Hegde M. Altered mitochondrial dynamics in motor neuron disease: an emerging perspective. *Cells* 2020;9:1065.
41. Tárnok K, Kiss E, Luiten PG, Nyakas C, Tihanyi K, Schlett K, et al. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. *Neurochem Int.* 2008;53:289–95.
42. Svab G, Doczi J, Gerencsér AA, Ambrus A, Gallyas F, Sümegi B, et al. The mitochondrial targets of neuroprotective drug vinpocetine on primary neuron cultures, brain capillary endothelial cells, synaptosomes, and brain mitochondria. *Neurochem Res.* 2019;44:2435–47.
43. PatientsLikeMe [online]. Available at: <https://www.patientslikeme.com/treatment/vinpocetine>. Accessed June 5, 2020.
44. ALS Net [online]. Available at: https://www.als.net/forum/yaf_postst48502p10_vinpocetine.aspx. Accessed June 5, 2020.
45. Al-Kuraishy H, Al-Gareeb A, Naji M, Al-Mamorry F. Role of vinpocetine in ischemic stroke and post-stroke outcomes: a critical review. *Brain Circ.* 2020;6:1–10.
46. Feigin V, Doronin B, Popova B, Gribatcheva E, Tchervov D. Vinpocetine treatment in acute ischemic stroke: a pilot single-blind randomized clinical trial. *Eur J Neurol.* 2001;8:81–5.
47. Ogunrin A. Effect of vinpocetine on cognitive performances of a Nigerian population. *Ann Med Health Sci Res.* 2014;4:654–61.
48. Covex [online]. Available at: <https://www.covex.com/products/api/vinpocetine/clinical-studies/efficacy-of-vinpocetine-in-the-management-of-cognitive-impairment-and-memory-loss/>. Accessed June 5, 2020.
49. Jha M, Rahman M, Sheikh H. Vinpocetine: a smart drug and a smart nutrient: a review. *IJPSR* 2012;3:346–52.
50. Priory [online]. Available at: <http://www.priory.com/med/vinpocetine.htm>. Accessed June 5, 2020.
51. Gavrilova SI, Kolykhalov IV, Fedorova YB, Selezneva ND, Kalyn YB, Roshchina IF, et al. Potential of preventive treatment of Alzheimer's disease: results of a three-year prospective open comparative trial of the efficacy and safety of courses of treatment with cerebrolysin and cavinton in elderly patients with mild cognitive impairment syndrome. *Neurosci Behav Physiol.* 2011;41:391–69.
52. Swanson [online]. Available at: https://www.swansonvitamins.com/source-naturals-vinpocetine-10-mg-60-tabs?SourceCode=INTL4071&DFA=1&UTM_Medium=Shopping&UTM_Source=GOOGLE&UTM_Campaign=SWAN_National_Gen_Shopping_Null_Null_All+Products_Medium+4055-01+Memory+and+Brain+Support&UTM_Content=PRODUCT_GROUP&SourceCode=INTL4071&ds_rl=1262629&ds_rl=1263854&ds_rl=1262629&gclid=EA1a1QobChMIzObx-ajr6QIV1uDICh3YmQHiEAQYASABEIGTvD_BwE. Accessed June 5, 2020.
53. Avula B, Chittiboyina AG, Sagi S, Wang Y-H, Wang M, Khan IA, et al. Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. *Drug Test Anal.* 2016;8:334–343.